Turmeric extract for the prevention of MI

Evaluation of Curcumin anti-inflammatory effects on peripheral blood mononuclear cells in coronary artery disease and plaque stabilization serum level of CD40L

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013081114330N1

Enrollment

Registered

2013-08-30

Start date

2013-09-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAD. Chronic ischaemic heart disease

Interventions

Intervention 1: The intervention group received routine treatment of heart disease in accordance with, the administration of curcumin. 1 Soft gel ((SinaCurcumin® (as nano-micelle 80 mg/day)) will be g

Treatment - Drugs

The intervention group received routine treatment of heart disease in accordance with, the administration of curcumin. 1 Soft gel ((SinaCurcumin® (as nano-micelle 80 mg/day)) will be gave to patients

control group: in this group, the patients with less than 50% obstruction in coronary artery and have medical follow up will take their medications and placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: diagnosis of CAD; age above 18-75 years old; giving informed consent. Exclusion criteria: diabetes (assessed by measuring 126 <FBS); renal failure (with BUN, Cr); liver failure (evaluation of liver enzymes ALT, AST and bilirubin); drugs inhibit the immune system; taking pentoxifylline; taking cilostazol; an underlying infectious or inflammatory diseases (based on history and physical examination); having a history of sensitivity to curcumin (turmeric); high CRP (CRP) and Schiff Lvkvstvz the right (at least two positive CRP test qualitative biochemistry and CBC); taking glucosamine (due to inhibitory effects on the inflammatory NF?B); Egypt barberry extract, berberine (due to inhibitory effects on the inflammatory NF?B) and having a history of abuse syndromes induced absorption (based on history).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Effect of curcumin on the expression of cellular markers of inflammation (NF?B). Timepoint: Before and after study. Method of measurement: Gene expression and proteomics.	—

Secondary

Measure	Time frame
Plaque instability indirect parameters such as MMP9, CD40 concentration, and etc. Timepoint: Before the study and after stud. Method of measurement: Measurement of CD40L.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Reza Rahimi

Mashhad University of Medical Sciences

rahimihr89+1@mums.ac.ir+98 51 1800 2301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026